Apramycin
Clinical data | |
---|---|
Trade names | Apralan |
AHFS/Drugs.com | International Drug Names |
ATCvet code | |
Legal status | |
Legal status | |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
DrugBank | |
ChemSpider | |
UNII | |
KEGG | |
ChEBI | |
ChEMBL | |
CompTox Dashboard (EPA) | |
ECHA InfoCard | 100.048.582 |
Chemical and physical data | |
Formula | C21H41N5O11 |
Molar mass | 539.583 g·mol−1 |
3D model (JSmol) | |
| |
| |
(what is this?) (verify) |
Apramycin (also Nebramycin II) is an aminoglycoside antibiotic used in veterinary medicine. It is produced by Streptomyces tenebrarius.[2]
Spectrum of bacterial susceptibility and resistance[edit]
Apramycin can be used to treat bacterial infections in animals caused by Escherichia coli, Klebsiella pneumoniae, and Pseudomonas aeruginosa.[citation needed] The following shows susceptibility data on medically significant organisms:
- Escherichia coli - 1 μg/mL - >512 μg/mL (this large range may be due to resistant organisms, typical MIC values are likely in the range of 2 -8 μg/mL.
- Klebsiella pneumoniae - 2 μg/mL - >256 μg/mL
- Pseudomonas aeruginosa - 4 μg/mL[3]
References[edit]
- ^ "Health product highlights 2021: Annexes of products approved in 2021". Health Canada. 3 August 2022. Retrieved 25 March 2024.
- ^ Ryden R, Moore BJ (November 1977). "The in vitro activity of apramycin, a new aminocyclitol antibiotic". The Journal of Antimicrobial Chemotherapy. 3 (6): 609–613. doi:10.1093/jac/3.6.609. PMID 340441.
- ^ "Apramycin". KnowledgeBase: The Antimicrobial Index.